(Washington, D.C.) Tomorrow could be a big day in the fight against the COVID-19 Pandemic as the FDA meets to discuss the Johnson & Johnson vaccine.

Last Thursday, Johnson & Johnson told congress it could get 20 million doses out nationwide if it’s approved.

Johnson & Johnson is only one dose shot and doesn’t require any special refrigeration compared to Pfizer and Moderna’s vaccines already on the market.

The only draw back of the Johnson and Johnson vaccine is that during trials it was about 25% less effective than the two vaccines.

Yesterday, Pfizer and Moderna also committed to an additional 145 million doses shipped nationwide by the end of March.